Spots Global Cancer Trial Database for acute myeloid leukemia in remission

Every month we try and update this database with for acute myeloid leukemia in remission cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia	NCT00453388	Acute Myeloid L... de Novo Myelody... Fanconi Anemia Previously Trea...	Allogeneic Bone... Cyclophosphamid... Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Nonmyeloablativ... Total-Body Irra...	-	Fred Hutchinson Cancer Center
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies	NCT01823198	Accelerated Pha... Acute Erythroid... Acute Megakaryo... Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... Blast Phase Chr... Blasts Under 20... Blasts Under 20... Chronic Myelomo... High Risk Myelo... Myelodysplastic... Recurrent Chron... Therapy-Related... Therapy-Related...	Aldesleukin Allogeneic CD56... Allogeneic Hema... Busulfan Fludarabine Pho... Laboratory Biom... Peripheral Bloo... Pharmacological...	7 Years - 65 Years	M.D. Anderson Cancer Center
Investigator-initiated Clinical Trial (Phase II) of Cancer Vaccine "Dainippon Sumitomo Phama(DSP)-7888" for Acute Myeloid Leukemia Patients.	NCT04747002	Acute Myeloid L...	DSP-7888	20 Years - 80 Years	Osaka University
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies	NCT03272633	Acute Lymphobla... Acute Myeloid L... Hematopoietic C... JAK2 Gene Mutat... Loss of Chromos... Mantle Cell Lym... Minimal Residua... Myelodysplastic... Non-Hodgkin Lym... Plasma Cell Mye... RAS Family Gene... Recurrent Diffu... Recurrent Hemat... Recurrent Matur... Refractory Diff... Refractory Matu... Therapy-Related... Therapy-Related... TP53 Gene Mutat...	Allogeneic Hema... Irradiated Allo...	18 Years -	Rutgers, The State University of New Jersey
Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis	NCT02528877	Acute Myeloid L... Primary Myelofi... Primary Myelofi... Secondary Acute... Secondary Myelo...	Allogeneic Bone... Allogeneic Hema... Fludarabine Pho... Laboratory Biom... Melphalan Peripheral Bloo... Pharmacological... Ruxolitinib Pho... Sirolimus Tacrolimus	18 Years - 75 Years	City of Hope Medical Center
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies	NCT02566304	Acute Myeloid L... Acute Myeloid L... Aplastic Anemia Chronic Myelomo... Hodgkin Lymphom... Indolent Non-Ho... Malignant Neopl... Myelodysplastic... Myeloproliferat... Plasma Cell Mye... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Refractory Cyto...	Fludarabine Total-Body Irra... T Cell-Depleted... Cyclophosphamid... Peripheral Bloo... Allogeneic Hema... Tacrolimus Mycophenolate m... Laboratory Biom...	18 Years -	Thomas Jefferson University
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome	NCT03670966	Acute Lymphobla... Acute Myeloid L... Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Recurrent Acute... Recurrent Acute... Refractory Acut... Refractory Acut... Recurrent Mixed... Refractory Mixe... Hematopoietic a...	Astatine At 211... Cyclophosphamid... Total-Body Irra... Peripheral Bloo... Bone Marrow Tra... Mycophenolate M... Recombinant Gra... Fludarabine Pho... Tacrolimus Bone Marrow Asp... Biospecimen Col...	18 Years - 75 Years	Fred Hutchinson Cancer Center
MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing	NCT05794880	Leukemia Acute Myeloid L... Myelodysplasia Acute Lymphobla... Chronic Myeloge... Chronic Myeloge... Chronic Myeloge... Biphenotypic Ac... Lymphoblastic L... Burkitt Lymphom... Burkitt Leukemi... Lymphoma After ... Other Malignant...	Magnetic-Activa...	0 Years - 25 Years	Medical College of Wisconsin
Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat	NCT04712942	Acute Myeloid L... Myelodysplastic... Minimal Residua...	Pevonedistat Azacitidine	18 Years -	University of Leipzig
NK Cells in Cord Blood Transplantation	NCT01619761	Accelerated Pha... Acute Biphenoty... Acute Lymphobla... Acute Myeloid L... Chronic Phase C... DS Stage II Pla... DS Stage III Pl... High Grade B-Ce... ISS Stage II Pl... ISS Stage III P... Myelodysplastic... Recurrent Acute... Recurrent Acute... Recurrent Chron... Recurrent Hodgk... Recurrent Non-H... Recurrent Small... Refractory Acut... Refractory Chro... Refractory Hodg... Refractory Non-... Refractory Smal... Secondary Acute... Therapy-Related... Therapy-Related...	Allogeneic Hema... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Lenalidomide Melphalan Mycophenolate M... Natural Killer ... Rituximab Tacrolimus Total-Body Irra... Umbilical Cord ...	- 75 Years	M.D. Anderson Cancer Center
Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT	NCT05917405	Acute Myeloid L...	Fludarabine Busulfan ATG Clofarabine	18 Years - 99 Years	Nantes University Hospital
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning	NCT03852407	Acute Myeloid L... Myelodysplastic... Chronic Myeloid... Myeloproliferat... Myeloproliferat... Acute Lymphoid ... Multiple Myelom... Chronic Lymphoi... Non Hodgkin Lym... Hodgkin Lymphom...	Thymoglobulin Melphalan Fludarabine Cyclophosphamid	18 Years - 75 Years	University of Liege
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD	NCT02220985	Accelerated Pha... Acute Biphenoty... Acute Leukemia ... Acute Undiffere... Allogeneic Hema... Blast Phase Chr... Blastic Plasmac... Childhood Acute... Childhood Acute... Donor Lymphoblastic L... Myelodysplastic... Myelodysplastic... Myelodysplastic... Recurrent Acute... Recurrent Acute... Recurrent Child... Recurrent Child... Recurrent Chron... Refractory Acut... Refractory Acut... Acute Lymphobla... Acute Myeloid L...	Allogeneic Hema... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Methotrexate Mycophenolate M... Peripheral Bloo... Peripheral Bloo... Tacrolimus Thiotepa Total-Body Irra...	- 60 Years	Fred Hutchinson Cancer Center
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant	NCT02506933	Accelerated Pha... Acute Lymphobla... Acute Myeloid L... Chronic Lymphoc... Chronic Phase C... Cytomegaloviral... Hodgkin Lymphom... Lymphadenopathy Lymphoblastic L... Myelodysplastic... Myelofibrosis Myeloproliferat... Non-Hodgkin Lym...	Laboratory Biom... Multi-peptide C... Placebo	18 Years - 75 Years	City of Hope Medical Center
Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia	NCT03697707	Acute Myeloid L...	DCP-001	18 Years -	Mendus
Ruxolitinib + Allogeneic Stem Cell Transplantation in AML	NCT03286530	Acute Myeloid L... Acute Myeloid L... Allogeneic Stem...	Ruxolitinib	60 Years - 80 Years	Massachusetts General Hospital
Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome	NCT03494569	Acute Lymphobla... Acute Lymphobla... Acute Myeloid L... Acute Myeloid L... Hematopoietic C... Minimal Residua... Myelodysplastic... Secondary Acute...	Fludarabine Laboratory Biom... Melphalan Total Marrow Ir...	12 Years -	City of Hope Medical Center
MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing	NCT05794880	Leukemia Acute Myeloid L... Myelodysplasia Acute Lymphobla... Chronic Myeloge... Chronic Myeloge... Chronic Myeloge... Biphenotypic Ac... Lymphoblastic L... Burkitt Lymphom... Burkitt Leukemi... Lymphoma After ... Other Malignant...	Magnetic-Activa...	0 Years - 25 Years	Medical College of Wisconsin
Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat	NCT04712942	Acute Myeloid L... Myelodysplastic... Minimal Residua...	Pevonedistat Azacitidine	18 Years -	University of Leipzig
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies	NCT02566304	Acute Myeloid L... Acute Myeloid L... Aplastic Anemia Chronic Myelomo... Hodgkin Lymphom... Indolent Non-Ho... Malignant Neopl... Myelodysplastic... Myeloproliferat... Plasma Cell Mye... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Refractory Cyto...	Fludarabine Total-Body Irra... T Cell-Depleted... Cyclophosphamid... Peripheral Bloo... Allogeneic Hema... Tacrolimus Mycophenolate m... Laboratory Biom...	18 Years -	Thomas Jefferson University
Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant	NCT03438344	Accelerated Pha... Acute Lymphobla... Acute Myeloid L... Bone Marrow Tra... Chronic Lymphoc... Chronic Phase C... Hematopoietic C... Hodgkin Lymphom... Myelodysplastic... Myelofibrosis Myeloproliferat... Non-Hodgkin Lym...	Multi-antigen C... Laboratory Biom... Placebo	18 Years -	City of Hope Medical Center
Ruxolitinib + Allogeneic Stem Cell Transplantation in AML	NCT03286530	Acute Myeloid L... Acute Myeloid L... Allogeneic Stem...	Ruxolitinib	60 Years - 80 Years	Massachusetts General Hospital
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant	NCT03192397	Acute Myeloid L... Adult Acute Lym... Chronic Myeloge... Chronic Myelomo... Graft Versus Ho... Hodgkin Lymphom... Minimal Residua... Myelodysplastic... Myeloproliferat... Non-Hodgkin Lym... Plasma Cell Mye... Severe Aplastic... Waldenstrom Mac...	Allogeneic Hema... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Melphalan Hydro... Mycophenolate M... Sirolimus Total-Body Irra...	18 Years -	Roswell Park Cancer Institute
Ruxolitinib + Allogeneic Stem Cell Transplantation in AML	NCT03286530	Acute Myeloid L... Acute Myeloid L... Allogeneic Stem...	Ruxolitinib	60 Years - 80 Years	Massachusetts General Hospital
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies	NCT03272633	Acute Lymphobla... Acute Myeloid L... Hematopoietic C... JAK2 Gene Mutat... Loss of Chromos... Mantle Cell Lym... Minimal Residua... Myelodysplastic... Non-Hodgkin Lym... Plasma Cell Mye... RAS Family Gene... Recurrent Diffu... Recurrent Hemat... Recurrent Matur... Refractory Diff... Refractory Matu... Therapy-Related... Therapy-Related... TP53 Gene Mutat...	Allogeneic Hema... Irradiated Allo...	18 Years -	Rutgers, The State University of New Jersey
Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant	NCT03438344	Accelerated Pha... Acute Lymphobla... Acute Myeloid L... Bone Marrow Tra... Chronic Lymphoc... Chronic Phase C... Hematopoietic C... Hodgkin Lymphom... Myelodysplastic... Myelofibrosis Myeloproliferat... Non-Hodgkin Lym...	Multi-antigen C... Laboratory Biom... Placebo	18 Years -	City of Hope Medical Center
Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes	NCT01690520	Acute Biphenoty... Acute Lymphobla... Acute Myeloid L... Chronic Myeloge... Myelodysplastic...	Cyclophosphamid... Cyclosporine Ex Vivo-Expande... Fludarabine Pho... Mycophenolate M... Thiotepa Total-Body Irra... Umbilical Cord ...	6 Months - 65 Years	Nohla Therapeutics, Inc.
MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing	NCT05794880	Leukemia Acute Myeloid L... Myelodysplasia Acute Lymphobla... Chronic Myeloge... Chronic Myeloge... Chronic Myeloge... Biphenotypic Ac... Lymphoblastic L... Burkitt Lymphom... Burkitt Leukemi... Lymphoma After ... Other Malignant...	Magnetic-Activa...	0 Years - 25 Years	Medical College of Wisconsin
Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia	NCT04232241	Acute Myeloid L... Acute Lymphobla... Myelodysplastic...	Allogeneic Stem...	18 Years - 70 Years	Universitätsklinikum Hamburg-Eppendorf
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies	NCT02566304	Acute Myeloid L... Acute Myeloid L... Aplastic Anemia Chronic Myelomo... Hodgkin Lymphom... Indolent Non-Ho... Malignant Neopl... Myelodysplastic... Myeloproliferat... Plasma Cell Mye... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Refractory Cyto...	Fludarabine Total-Body Irra... T Cell-Depleted... Cyclophosphamid... Peripheral Bloo... Allogeneic Hema... Tacrolimus Mycophenolate m... Laboratory Biom...	18 Years -	Thomas Jefferson University
Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft	NCT03887156	Acute Myeloid L... Lymphoma in Rem... Non-progressive... Myelodysplasia ... Acute Leukemia ... Acute Lymphobla...	Ex vivo capacit...	18 Years - 65 Years	Assistance Publique - Hôpitaux de Paris
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant	NCT02506933	Accelerated Pha... Acute Lymphobla... Acute Myeloid L... Chronic Lymphoc... Chronic Phase C... Cytomegaloviral... Hodgkin Lymphom... Lymphadenopathy Lymphoblastic L... Myelodysplastic... Myelofibrosis Myeloproliferat... Non-Hodgkin Lym...	Laboratory Biom... Multi-peptide C... Placebo	18 Years - 75 Years	City of Hope Medical Center
AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission	NCT04062266	Acute Myeloid L... FLT3 Gene Mutat... Hematologic and... Acute Myeloid L... Minimal Residua... Therapy-Related...	Azacitidine Venetoclax	18 Years -	M.D. Anderson Cancer Center
Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AML	NCT04490707	Acute Myeloid L...	Azacitidine Lenalidomide	60 Years - 80 Years	Zhongda Hospital
Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia	NCT04232241	Acute Myeloid L... Acute Lymphobla... Myelodysplastic...	Allogeneic Stem...	18 Years - 70 Years	Universitätsklinikum Hamburg-Eppendorf
Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant	NCT02083250	Acute Lymphobla... Acute Myeloid L... Allogeneic Hema... Myelodysplastic... Previously Trea... Recurrent Acute... Recurrent Acute...	Allogeneic Bone... Allogeneic Hema... Anti-Thymocyte ... Busulfan Clofarabine Fludarabine Pho... Peripheral Bloo... Pharmacological... Vorinostat	- 60 Years	M.D. Anderson Cancer Center
Aerobic Versus Resistive Training on Functional Capacity in Acute Myeloid Leukemia	NCT04617145	Acute Myeloid L...	Aerobic exercis...	35 Years - 45 Years	Cairo University
Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies	NCT01413568	Acute Myeloid L... Adult Acute Lym... Chronic Myeloge... Non-Hodgkin's L... Chronic Lymphoc... Multiple Myelom... Myelodysplastic... Myeloproliferat...	POL6326 Leukapheresis PBSC Transplant	18 Years - 75 Years	Polyphor Ltd.
Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant	NCT02083250	Acute Lymphobla... Acute Myeloid L... Allogeneic Hema... Myelodysplastic... Previously Trea... Recurrent Acute... Recurrent Acute...	Allogeneic Bone... Allogeneic Hema... Anti-Thymocyte ... Busulfan Clofarabine Fludarabine Pho... Peripheral Bloo... Pharmacological... Vorinostat	- 60 Years	M.D. Anderson Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: